drugset / Trial / NCT06745518

A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

NCT06745518

Phase 2 Completed 62 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 2, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Timeline

Start
2025-01-06
Primary completion
2025-07-15
Completion
2025-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral
Subject TS-172 Unknown 60 mg Oral

Indications